Becton Dickinson in its public notes offering to fund in part the acquisition of the Edwards Lifesciences Corporation

On June 4, 2024, Becton, Dickinson and Company announced and priced registered public offerings of €1 billion aggregate principal amount of 3.828% notes due 2032 and $600 million aggregate principal amount of 5.081% notes due 2029.  BD also announced and priced a registered public offering by its finance subsidiary, Becton Dickinson Euro Finance S.à r.l., of €800 million aggregate principal amount of 4.029% notes due 2036.  BD expects to use the net proceeds from the offerings to fund in part the cash consideration payable by BD for the acquisition of the Critical Care business of Edwards Lifesciences Corporation, for fees and expenses in respect of the foregoing, and for general corporate purposes.

Wachtell, Lipton, Rosen & Katz is serving as legal advisor to BD.